Study Overview
This study looked at the MiniMed 780G system, a new diabetes technology, and how it compares to older insulin treatments for people with type 1 diabetes (T1D) in the US.
Key Findings
- The MiniMed 780G system helps improve blood sugar control.
- It is cost-effective, meaning it provides good health benefits for the money spent.
- The cost-effectiveness was measured in terms of quality-adjusted life years (QALYs).
Cost-Effectiveness Results
In the study:
- Over 4 years, the MiniMed 780G system costs about $68,402 for each additional year of healthy life.
- Over a lifetime, this cost drops to about $38,842 per additional year of healthy life.
These figures are below the commonly accepted threshold of $100,000, indicating that the MiniMed 780G system is a good investment for patients and healthcare providers.
Opportunities for Clinics and Patients
Based on the trial data, clinics can:
- Set clear goals for improving diabetes management with the MiniMed 780G system.
- Measure outcomes like blood sugar levels and quality of life effectively.
- Consider implementing AI tools to enhance diabetes care.
Next Steps
Clinics interested in using the MiniMed 780G system should:
- Start with a pilot project to test the system.
- Track results and adjust strategies based on real-world outcomes.
Contact Us
For more information about AI solutions in medical management, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
